当前位置: X-MOL 学术Helicobacter › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection
Helicobacter ( IF 4.3 ) Pub Date : 2021-08-12 , DOI: 10.1111/hel.12840
Ping-I Hsu, Feng-Woei Tsay, John Y. Kao, Nan-Jing Peng, Yan-Hua Chen, Sheng-Yeh Tang, Chao-Hung Kuo, Sung-Shuo Kao, Huay-Min Wang, I-Ting Wu, Chang-Bih Shie, Seng-Kee Chuah, Deng-Chyang Wu

The Maastricht V/Florence Consensus Report recommends amoxicillin-fluoroquinolone triple or quadruple therapy as a second-line treatment for Helicobacter pylori infection. An important caveat of amoxicillin-fluoroquinolone rescue therapy is poor eradication efficacy in the presence of fluoroquinolone resistance. The study aimed to investigate the efficacies of tetracycline-levofloxacin (TL) quadruple therapy and amoxicillin-levofloxacin (AL) quadruple therapy in the second-line treatment of H. pylori infection.

中文翻译:

四环素-左氧氟沙星与阿莫西林-左氧氟沙星四联疗法在幽门螺杆菌感染二线治疗中的比较

Maastricht V/Florence Consensus Report 推荐阿莫西林-氟喹诺酮三联或四联疗法作为幽门螺杆菌感染的二线治疗。阿莫西林-氟喹诺酮类药物抢救治疗的一个重要警告是,在氟喹诺酮类耐药的情况下,根除效果不佳。该研究的目的是调查四环素左氧氟沙星(TL)四联疗法在第二线治疗的功效和阿莫西林-左氧氟沙星(AL)四联疗法ħ 幽门螺杆菌感染。
更新日期:2021-09-13
down
wechat
bug